IL161801A0 - Unsaturated amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists - Google Patents
Unsaturated amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonistsInfo
- Publication number
- IL161801A0 IL161801A0 IL16180102A IL16180102A IL161801A0 IL 161801 A0 IL161801 A0 IL 161801A0 IL 16180102 A IL16180102 A IL 16180102A IL 16180102 A IL16180102 A IL 16180102A IL 161801 A0 IL161801 A0 IL 161801A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- nicotinic receptor
- neuronal nicotinic
- unsaturated amino
- alkylcyclohexane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/25—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35097401P | 2001-11-07 | 2001-11-07 | |
| US33785801P | 2001-11-08 | 2001-11-08 | |
| PCT/GB2002/005038 WO2003040084A1 (en) | 2001-11-07 | 2002-11-07 | Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161801A0 true IL161801A0 (en) | 2005-11-20 |
Family
ID=26990903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16180102A IL161801A0 (en) | 2001-11-07 | 2002-11-07 | Unsaturated amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6828462B2 (hu) |
| EP (1) | EP1442008A1 (hu) |
| JP (1) | JP2005508381A (hu) |
| KR (1) | KR100655975B1 (hu) |
| CN (1) | CN100390131C (hu) |
| AU (1) | AU2002337389B2 (hu) |
| CA (1) | CA2465738C (hu) |
| CO (1) | CO5570696A2 (hu) |
| EA (1) | EA010177B1 (hu) |
| GE (1) | GEP20053714B (hu) |
| HK (1) | HK1075037A1 (hu) |
| HU (1) | HUP0402028A3 (hu) |
| IL (1) | IL161801A0 (hu) |
| MX (1) | MXPA04004412A (hu) |
| NO (1) | NO20042338L (hu) |
| PL (1) | PL370245A1 (hu) |
| WO (1) | WO2003040084A1 (hu) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW593223B (en) * | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| EP1660058A2 (en) * | 2003-07-28 | 2006-05-31 | Merz Pharma GmbH & Co. KGaA | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
| AR046314A1 (es) * | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| CA2568445C (en) * | 2004-06-17 | 2011-05-24 | Merz Pharma Gmbh & Co. Kgaa | Immediate release formulations of memantine oral dosage forms |
| US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EP2117315A1 (en) * | 2007-02-21 | 2009-11-18 | SSV Therapeutics, Inc. | Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids |
| EP2111858A1 (en) | 2008-04-25 | 2009-10-28 | EPFL Ecole Polytechnique Fédérale de Lausanne | Novel treatment for alzheimer's disease |
| US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
| EA021399B1 (ru) | 2008-08-12 | 2015-06-30 | Зинфандел Фармасьютикалз, Инк. | Способ идентификации факторов риска заболеваний |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| KR20180050420A (ko) | 2011-01-10 | 2018-05-14 | 진판델 파마슈티컬스 인코포레이티드 | 알츠하이머 병 치료를 위한 방법 및 약품 |
| US20150182546A1 (en) * | 2013-03-15 | 2015-07-02 | Mitochondrial Concepts Llc | Therapeutic agent for enhancing mitochondrial function |
| EP3568388A4 (en) * | 2017-01-10 | 2020-10-14 | Owen-Barry Pharmaceuticals Inc. | ANTICONVULSIVE CONNECTIONS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267366A (en) * | 1977-12-14 | 1981-05-12 | Scm Corporation | Cyclic terpenoid amines, their preparation and uses |
| GEP20032995B (en) * | 1997-06-30 | 2003-06-25 | Merz & Co Gmbh & Co | 1-Amino-Alkylcyclohexane NMDA Receptor Antagonists |
| US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
-
2002
- 2002-11-06 US US10/288,819 patent/US6828462B2/en not_active Expired - Fee Related
- 2002-11-07 AU AU2002337389A patent/AU2002337389B2/en not_active Ceased
- 2002-11-07 HU HU0402028A patent/HUP0402028A3/hu unknown
- 2002-11-07 EA EA200400637A patent/EA010177B1/ru not_active IP Right Cessation
- 2002-11-07 JP JP2003542132A patent/JP2005508381A/ja active Pending
- 2002-11-07 WO PCT/GB2002/005038 patent/WO2003040084A1/en active IP Right Grant
- 2002-11-07 PL PL02370245A patent/PL370245A1/xx not_active Application Discontinuation
- 2002-11-07 KR KR1020047006901A patent/KR100655975B1/ko not_active IP Right Cessation
- 2002-11-07 CA CA002465738A patent/CA2465738C/en not_active Expired - Fee Related
- 2002-11-07 GE GE5600A patent/GEP20053714B/en unknown
- 2002-11-07 EP EP02772631A patent/EP1442008A1/en not_active Withdrawn
- 2002-11-07 IL IL16180102A patent/IL161801A0/xx unknown
- 2002-11-07 CN CNB02824530XA patent/CN100390131C/zh not_active Expired - Fee Related
- 2002-11-07 MX MXPA04004412A patent/MXPA04004412A/es active IP Right Grant
-
2004
- 2004-05-06 CO CO04041831A patent/CO5570696A2/es not_active Application Discontinuation
- 2004-06-04 NO NO20042338A patent/NO20042338L/no not_active Application Discontinuation
-
2005
- 2005-08-22 HK HK05107277.4A patent/HK1075037A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0402028A2 (hu) | 2005-01-28 |
| US20030166634A1 (en) | 2003-09-04 |
| CA2465738A1 (en) | 2003-05-15 |
| CO5570696A2 (es) | 2005-10-31 |
| CA2465738C (en) | 2009-01-20 |
| KR100655975B1 (ko) | 2006-12-08 |
| CN1602292A (zh) | 2005-03-30 |
| WO2003040084A1 (en) | 2003-05-15 |
| US6828462B2 (en) | 2004-12-07 |
| HK1075037A1 (en) | 2005-12-02 |
| JP2005508381A (ja) | 2005-03-31 |
| KR20050044354A (ko) | 2005-05-12 |
| HUP0402028A3 (en) | 2008-03-28 |
| CN100390131C (zh) | 2008-05-28 |
| EP1442008A1 (en) | 2004-08-04 |
| GEP20053714B (en) | 2005-12-26 |
| EA010177B1 (ru) | 2008-06-30 |
| EA200400637A1 (ru) | 2004-10-28 |
| PL370245A1 (en) | 2005-05-16 |
| AU2002337389B2 (en) | 2005-12-08 |
| NO20042338L (no) | 2004-07-21 |
| MXPA04004412A (es) | 2005-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1075037A1 (en) | Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists | |
| PL365377A1 (en) | Amide derivatives as nmda receptor antagonists | |
| EP1436258A4 (en) | ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH | |
| AU2002347022A1 (en) | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten | |
| HK1064100A1 (en) | Adenosine a 2a receptor antagonists | |
| PL369731A1 (en) | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists | |
| TWI319764B (en) | Mercaptoacetylamide derivatives, a process for their preparation and their use | |
| IL161716A0 (en) | ADENOSINE A2a RECEPTOR ANTAGONISTS | |
| EP1351933A4 (en) | ANTAGONISTS OF IL-8 RECEPTORS | |
| HK1064097A1 (en) | Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists | |
| EP1373508A4 (en) | HUMAN CYTOKIN RECEPTOR | |
| IL153170A0 (en) | Bicyclic cyclohexylamines and their use as nmda receptor antagonists | |
| AU2002365655A1 (en) | 5-ht7 receptor antagonists | |
| EP1370676A4 (en) | CYTOKIN RECEPTOR FROM MOUSE | |
| ZA200104187B (en) | 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists. | |
| HK1063791A1 (en) | Nk1 antagonists | |
| AU2002351730A1 (en) | Glucagon receptor antagonists/inverse agonists | |
| EP1296958A4 (en) | ANTIAGONISTS OF NMDA NR2B RECEPTORS OF IMINOPYRIMIDINE | |
| EP1359915A4 (en) | UROTENSIN-II RECEPTOR ANTAGONISTS | |
| EP1537083A4 (en) | S - (-) - AMLODIPINNICOTINATE AND METHOD FOR THE PRODUCTION THEREOF | |
| AU2002216079A1 (en) | Bombesin receptor antagonists | |
| AU2002359524A8 (en) | P2x7 receptor antagonists | |
| PL372701A1 (en) | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane as nmda, 5ht3, and neuronal nicotinic receptor antagonists | |
| AU2002325164A1 (en) | Receptor, the use thereof, and mouse antibodies | |
| AU2002217095A1 (en) | Bombesin receptor antagonists |